Using multiple samples from more than 60,000 individuals at a participating hospital, the firm tracks circulating molecules over time in relation to cancer.
Researchers in the US and Ukraine built a microRNA-based classifier to categorize infants as affected or unaffected.
Researchers from Northwestern University uncovered five circulating microRNAs that differentiate patients with very high- and low-risk prostate cancer.
The company sees microRNAs as the ideal blood-based biomarker for diagnosing and monitoring a number of diseases at the point of care and in the developing world.
UK researchers have technically validated a qPCR testing method for a panel of four microRNAs with high sensitivity in diagnosing and monitoring rare tumors.
The company provided updates on its pipeline of NGS cancer assays, including plans to launch a lung cancer fusion panel by the end of this year.
The team recently received funding to develop and validate an assay to help guide clinical decision making when pancreatic cancer precursor lesions are detected.
Unlike past efforts by other groups, the study will include individuals with polyps that give rise to colorectal cancer, not just cancer patients.
The company is developing a prototype system that it aims to later validate in clinical samples.
MiRxes, a Singapore-based startup focusing on microRNA research and diagnostics, officially launched earlier this month with a proprietary qPCR platform for identifying microRNA and other small RNA biomarkers.
The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.
Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.
In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.
China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.